Drug intelligence / Profile preview

ergotamine + paracetamol + caffeine

Development stage
Unknown
Lead developer
STERIS
Modality
Small Molecules
Administration
Oral
01

Overview

A multi-ingredient oral pharmaceutical formulation combining **ergotamine** (an ergot alkaloid and vasoconstrictor acting on cranial blood vessels), **paracetamol** (also known as acetaminophen, a non-opioid analgesic and antipyretic that inhibits prostaglandin synthesis in the central nervous system), and **caffeine** (a methylxanthine, central nervous system stimulant that enhances the vasoconstrictive effect of ergotamine and increases absorption and analgesic efficacy of paracetamol). The combination is primarily used for the **acute treatment of migraine attacks** (with or without aura) and severe headache, reducing head pain, sensitivity to light and sound, and, in combination formulations, sometimes nausea and vomiting. The combination is available under brand names (e.g., ANTIMIRGRAIN) and is indicated for adults.

Brand names
ANTIMIRGRAIN
Other names
ergotamine tartrate + paracetamol + caffeine
02

Targets

COX-1 (Prostaglandin G/H synthase 1)HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)DRD2 (Dopamine D2 Receptor)ADRA1 (Alpha-1 adrenergic receptor family)PTGS2 (Prostaglandin G/H synthase 2)ADOR (Adenosine receptors)

Beyond the preview

Go deeper on ergotamine + paracetamol + caffeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ergotamine + paracetamol + caffeine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call